Bright Minds Biosciences Inc Stock Price, News & Analysis

Bright Minds Biosciences (NASDAQ: DRUG) closed a public offering of 1,945,000 common shares at US$90.00 per share for gross proceeds of US$175,050,000 on January 9, 2026. The company granted the underwriters a 30-day option to purchase up to an additional 291,750 shares at the offering price, less discounts and commissions. Net proceeds are intended to fund clinical trials for candidates targeting absence seizures, DEE, and Prader-Willi syndrome, initiate phase 1 trials for BMB-105, support earlier-stage R&D, and for general corporate and working capital purposes. Jefferies, TD Cowen, Piper Sandler, and Cantor acted as joint book-running managers. The offering was made under a Form F-3 registration statement declared effective September 2, 2025.

Bright Minds Biosciences (NASDAQ: DRUG) priced an upsized public offering of 1,945,000 common shares at $90.00 per share for anticipated gross proceeds of $175,050,000. The underwriters have a 30-day option to buy up to an additional 291,750 shares. Closing is expected on January 9, 2026 subject to customary conditions. Net proceeds are intended to fund clinical trials (including absence seizures, DEE, Prader-Willi syndrome), initiation of a phase 1 trial for BMB-105, earlier R&D programs, and general corporate purposes. The company also terminated its prior ATM program that had up to $100M capacity.

Bright Minds Biosciences (NASDAQ: DRUG) announced a public offering to raise aggregate gross proceeds of US$100 million by selling common shares and, optionally, pre-funded warrants on January 6, 2026. The company granted underwriters a 30-day option to purchase up to an additional 15% of the Common Shares issued in the Offering.

Proceeds are intended to fund clinical trials for absence seizures, developmental and epileptic encephalopathy (DEE), and Prader-Willi syndrome, to initiate phase 1 trials for BMB-105, support earlier-stage R&D, and for general corporate and working capital purposes. The shelf registration on Form F-3 was declared effective by the SEC on September 2, 2025. Prospectus materials will be filed with the SEC and are available on EDGAR.

Bright Minds Biosciences (Nasdaq: DRUG) reported positive topline Phase 2 BREAKTHROUGH results for BMB-101 in adult patients with drug-resistant Absence Seizures and developmental and encephalopathic epilepsies (DEE) on January 6, 2026.

Key results: 73.1% median reduction in absence seizures ≥3s (n=11; p=0.012), 63.3% median reduction in major motor seizures in DEE (n=6), and a 90% mean increase in REM sleep without change in total sleep time. 24 patients were enrolled; safety was generally favorable with mostly mild/moderate AEs and no treatment-related serious adverse events. The company is preparing global registrational trials and plans additional data releases and a Q1 2026 PWS study.

Bright Minds Biosciences (NASDAQ:DRUG) will report topline Phase 2 results for BMB-101 on January 6, 2026 at 8:00 AM ET. The company said the announcement covers patients with drug-resistant absence seizures and developmental and epileptic encephalopathy.

A live conference call and webcast will present the data, include a discussion and a Q&A session, and a replay will be posted in the company’s Investors > Events and Presentations section after the event. Participants can submit questions using the webcast "Questions" tab.

Bright Minds Biosciences (NASDAQ: DRUG) will present at two industry events in early December 2025 highlighting its work on selective 5-HT2 agonists for drug-resistant epilepsy, depression, and other CNS disorders.

Events and schedule: Piper Sandler 37th Annual Healthcare Conference on Dec 3, 2025 at 11:30am ET, and the 2025 American Epilepsy Society Annual Meeting scientific exhibit session on Dec 7, 2025 from 2:00pm–5:00pm ET. The appearances provide investor and scientific audiences opportunities to hear updates and view the company’s scientific exhibit.

Bright Minds Biosciences (NASDAQ: DRUG) announced four additions to its Scientific Advisory Board to support its Prader-Willi syndrome (PWS) program and clinical development of BMB-101 and BMB-105 on November 17, 2025. The company held a KOL event on November 6, 2025 announcing the PWS program and nomination of BMB-105. The NOVA study is a double-blind, randomized Phase 2a trial up to 16 weeks with a 4-week screening, 4-week MTD titration, 8-week maintenance, and optional open-label extension up to 9 months. Primary endpoint is change in HQ-CT hyperphagia scores; secondary endpoints include CGI and caregiver measures.

Bright Minds Biosciences (NASDAQ: DRUG) announced the initiation of a Prader-Willi Syndrome (PWS) program and nomination of BMB-105 as a clinical candidate, and will host a KOL webcast on November 6, 2025 at 10:00 AM ET. The company will start a randomized double-blind Phase 2a (NOVA) study of BMB-101 (up to 16 weeks) to assess efficacy, safety, and tolerability on hyperphagia and neuropsychiatric symptoms, and a Phase 1 study of BMB-105 in healthy volunteers. Management targets topline data release for the epilepsy program in early January 2026 and expects to accelerate PWS development by ~one year.

Bright Minds Biosciences (NASDAQ: DRUG) will present at two investor conferences in November 2025: the Jefferies Global Healthcare Conference in London on November 10, 2025 at 12:00pm GMT (7:00am ET) and the Guggenheim 2nd Annual Healthcare Innovation Conference on November 12, 2025 at 9:00am ET.

The Guggenheim presentation will be available live and archived via webcast; a replay will be accessible from the company website for 60 days. There is no webcast for the Jefferies event. In addition, the company granted stock options to certain directors, officers and consultants to purchase an aggregate 43,000 common shares at an exercise price of US$54.47 per share, exercisable for five years and subject to vesting over the option term.